VIVUS, Inc. (VVUS) Tumbles on Concerns About Generic Qsymia  
8/20/2012 7:18:04 AM

Shares of Vivus Inc. stumbled Friday after an analyst slashed his sales estimates for Vivus' new obesity drug Qsymia, saying many physicians may prescribe Qsymia's ingredients for their patients instead of the drug itself. THE SPARK: Analyst Thomas Wei said he now believes a significant number of physicians will prescribe the two drugs that comprise Qsymia instead of giving their patients Qsymia itself, and that will cut into the drug's sales. Wei said he now thinks sales of Qsymia will peak at $1.2 billion a year, far below his previous estimate of $3.6 billion per year.